
This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Synthesis of (2'*S*)-1-(2-*C*-Azidomethyl-2-deoxy and 2-*C*-Cyanomethyl-2-deoxy-β-D-arabinofuranosyl)cytosines

Yuichi Yoshimura^a; Hiroshi Satoh^a; Shinji Sakata^a; Noriyuki Ashida^a; Shuichi Miyazaki^a; Akira Matsud^b ^a R & D Division, Yamasa Corporation, Choshi, Chiba, Japan ^b Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

To cite this Article <code>Yoshimura</code>, <code>Yuichi</code>, <code>Satoh</code>, <code>Hiroshi</code>, <code>Sakata</code>, <code>Shinji</code>, <code>Ashida</code>, <code>Noriyuki</code>, <code>Miyazaki</code>, <code>Shuichi</code> and <code>Matsud</code>, <code>Akira(1995)</code> 'Synthesis of (2'S)-1-(2-C-Azidomethyl-2-deoxy and 2-C-Cyanomethyl-2-deoxy- β -D-arabinofuranosyl)cytosines', <code>Nucleosides</code>, <code>Nucleotides</code> and <code>Nucleic</code> <code>Acids</code>, 14: 3, 427 - 429

To link to this Article: DOI: 10.1080/15257779508012400 URL: http://dx.doi.org/10.1080/15257779508012400

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF (2'S)-1-(2-C-AZIDOMETHYL-2-DEOXY AND 2-C-CYANOMETHYL-2-DEOXY-β-D-ARABINOFURANOSYL)CYTOSINES

Yuichi Yoshimura*, Hiroshi Satoh, Shinji Sakata, Noriyuki Ashida, Shuichi Miyazaki, and Akira Matsuda†

R & D Division, Yamasa Corporation, 2-10-1 Araoi-cho, Choshi, Chiba 288 Japan [†]Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060 Japan

ABSTRACT: 2'-C-Cyanomethyl-2'-deoxy-arabinosylcytosine **3** and 2'-C-azidomethyl-2'-deoxy-arabinosylcytosine **4** were synthesized from uridine. The antineoplastic activities of these compounds were evaluated.

Developing new drugs effective for cancer chemotherapy is one of the target for synthetic nucleoside antimetabolites. Many efforts have been made to synthesize a number of nucleoside analogues and some 2'-C-substituted 2'-deoxycytidine derivatives show potent antineoplastic activities.

HO

1: X = H (SMDC)

2: X = F (SFDC)

3: X = CN

4: $X = N_3$

For example, (2'S)-1-(2-Deoxy-2-C-methylarabinofuranosyl)cytosine 1 (SMDC) and its fluoromethyl derivative 2 (SFDC) have antileukemic activities *in vitro*. ^{1,2} These results prompted us to synthesize SMDC derivatives bearing an electron-withdrawing substituent at the 2'-methyl group. In this report we describe the synthesis and the antineoplastic activity of cyano and azido substituted SMDC analogues (Chart 1).

2'-Ketouridine 5³, easily obtained from uridine, was treated with cyanomethylenetriphenylphosphorane to give cyanomethylene uridine 6 in good yield. Compound 6 was reduced by sodium borohydride to give β-cyanomethyl derivative 7 stereoselectively.⁴ The bulky 1'-heterocyclic moiety blocked the hydride approaching from the β-side and this should


Chart 1

cause stereoselective reduction. The cyanomethyluridine 7 was converted to the cytidine analogue 8, using the triazole method⁵ and, finally, the protecting group was removed by tetrabutylammonium fluoride (TBAF) treatment to furnish 3 (Scheme 1).

The branched nucleoside 96 was selectively deacetylated by triethylamine-MeOH to afford *cis*-diol 10. The *tert*-alcohol of 10 was removed by the radical deoxygenation of cyclic thiocarbonate 11, which was obtained from 10 by treatment with 1, 1'-thiocarbonyldiimidazole, using tributyltin hydride in

428 YOSHIMURA ET AL.

Scheme 1



Scheme 2

the presence of AIBN. The radical deoxygenation occurred regio- and stereoselectively, as expected, to give the 2'-deoxy-2'-C-hydroxymethylarabinosyluracil 12 in 56% yield.

For the introduction of the azido group at 2'-branched chain, the N-3 position had to be protected by a benzoyl group to avoid the formation of an anhydronucleoside.⁷ This was achieved by trimethylsilylation at the 2'-free hydroxyl group of **12**, followed by benzoylation at N-3 and acidic deprotection of TMS group. The Mitsunobu reaction of **13** using diphenyl phosphorylazide as the azide source⁷ afforded **14** in 78 % yield. After debenzoylation, the compound **15** was converted to 2'-*C*-azidomethyl-2'-deoxy-arabinosylcytosine **4** by the method described above (Scheme 2).

The antineoplastic activities of 3 and 4 were evaluated. The azidomethyl derivative 4 showed weak activity toward human leukemic T-cells [CCRF-HSB-2 (IC₅₀ = 8.50 μ g/ml)], while the cyanomethyl derivative 3 was inactive (IC₅₀ = 44.7 μ g/ml). Both compounds were inactive against solid tumor cells [KB cells (IC₅₀ = >10 μ g/ml)].

ACKNOWLEDGEMENT: The authors would like to thank Dr. A. Kuninaka (Yamasa Corporation) for critical reading of the manuscript, and, Mr. M. Morozumi and Dr. H. Machida for their helpful discussions.

REFERENCES

- a) Matsuda, A.; Takenuki, K.; Itoh, H.; Sasaki, T.; Ueda, T. Chem. Pharm. Bull. 1987, 35, 3967-3970.
 - b) Matsuda, A.; Takenuki, K.; Sasaki, T.; Ueda, T. J. Med. Chem. 1991, 34, 234-239.
- Yoshimura, Y.; Saitoh, K.; Ashida, N.; Sakata, S.; Matsuda, A. BioMed. Chem. Lett. 1994, 5, 721-724.
- 3. Hansske, F.; Madej, D.; Robins, M. J. Tetrahedron 1984, 40, 125-135.
- 4. Ueda, T.; Shuto, S.; Satoh, M.; Inoue, H. Nucleosides & Nucleotides 1985, 4, 401-409.
- 5. Divakar, K. J.; Reese, C. B. J. Chem. Soc. Perkin Trans. 1 1982, 1171-1176.
- 6. Sano, T.; Shuto, S.; Inoue, H.; Ueda, T. Chem. Pharm. Bull. 1985, 33, 3617-3622.
- 7. a) Matsuda, A.; Yasuoka, J.; Ueda, T. Chem. Pharm. Bull. 1989, 37, 1659-1661.
 - b) Matsuda, A.; Yasuoka, J.; Sasaki, T.; Ueda, T. J. Med. Chem. 1991, 34, 999-1002.